OR WAIT null SECS
July 19, 2024
Pluri’s newly launched CDMO business will manufacture two novel cell therapy product candidates for Kadimastem.
May 24, 2024
Under this partnership, AGC Biologics and BioConnection will provide development and manufacturing capabilities for biopharmaceutical drug substance and drug product.
May 23, 2024
The Mirus Bio acquisition will boost Merck KGaA’s viral vector manufacturing services.
May 04, 2024
A comparison between polysorbates and HPβCD determines the better stabilizer for biologics formulation.
April 26, 2024
Contract manufacturer SK pharmteco will manufacture as well as conduct testing and release of Ferring Pharmaceuticals’ Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy for bladder cancer.
April 04, 2024
Lonza has made a deal with Acumen Pharmaceuticals to manufacture sabirnetug, a mAb that will soon be entering Phase II development for treating Alzheimer’s disease.
March 19, 2024
Orchard Therapeutics’ Lenmeldy (atidarsagene autotemcel) marks the first gene therapy approved in the US for treating children with metachromatic leukodystrophy.
March 13, 2024
Under a new agreement, Chime Biologics will manufacture Domain Therapeutics’ antibody cancer immunotherapy candidate, DT-7012.
March 06, 2024
The company is expanding GMP capacities at its Frankfurt site to manufacture early clinical-phase peptide APIs.
February 28, 2024
The company is investing more than $250 million into its Bloomington, Ind. Manufacturing site.